Curevo Vaccine is reducing the burden of infectious diseases through the development of high effective vaccines. Adjuvanted sub-unit vaccines do not contain virus components and so do not cause infection, yet they produce an optimal immune response. Using a combination of expertise in immunology, protein science, adjuvant technology and regulatory operations, Curevo is creating safe and effective vaccines from the bench through to market to address global unmet clinical needs. Curevo’s first vaccine candidate, CRV-101, is an adjuvanted sub-unit vaccine for the protection from Shingles in older adults and for protection from Chickenpox in immunocompromised children. CRV-101 is currently in clinical trials.

Curevo Vaccine

Short description:

Drug notes:

Long description:

Jobs: